Skip to main content
OpenTrials
Completed

NCT Number: NCT03035643

DARTS I Feasibility Study

The objective of this study is to investigate the feasibility and clinical benefits of the AMDS to treat patients with acute DeBakey type I dissections and/or intramural hematomas (IMH) involving the ascending aorta and aortic arch through open surgical repair.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada

Loading trial locations.

About this study

AMDS is designed to complement the replacement of the ascending aorta with conventional surgical technique utilizing a conventional polyester graft. AMDS is constructed of an uncovered Nitinol wire braided stent attached proximally to a polytetrafluoroethylene (PTFE) felt graft component. The PFTE felt graft component excludes the FL at the distal aortic anastomosis and the wire stent re-expands the dissection flap within the arch and descending aorta, which aims to treat malperfusion and promote positive remodeling of the aorta.

The DARTS I Feasibility study is a prospective, non-randomized, non-blinded, single-arm, multi-institutional Canadian study evaluating the feasibility and safety of the AMDS graft. A goal of 40 subjects will be enrolled at approximately 5 sites in Canada.

The enrollment period will span a minimum of 12 months from Institutional Review Board (IRB) approval and site activation. Candidates for this study are adults who require repair of an acute DeBakey type I aorta dissection and/or intramural hematoma (IMH). Patients will be consented pre-operatively and enrolled patients will be followed for approximately 5 years after their AMDS implantation date. Data will be collected at 10 time points: baseline (pre-operatively), discharge, 1 month post-operatively, 3 months post-operatively, and 6 months post-operatively, 1 year post-operatively and thereafter, annually, for a total of 5 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject must have one of the following diagnosed, based on CT angiography, within 0-14 days:

  • Acute DeBakey type I dissection or
  • Acute DeBakey type I intramural hematoma (IMH)

Exclusion criteria

General Exclusion Criteria

Patients must be excluded from the study if any of the following conditions are true:

  • Less than 18 years of age or over 80 years of age
  • Life expectancy less than 2 years
  • Pregnant or breastfeeding or planning on becoming pregnant within 60 months
  • Unwilling to comply with the follow-up schedule
  • Refusal to give informed consent

Medical Exclusion Criteria

Patients must be excluded from the study if any of the following conditions are true:

  • Uncontrolled systemic infection
  • Uncontrollable anaphylaxis to iodinated contrast
  • Known allergy(ies) to Nitinol and/or PTFE
  • Patient in extreme hemodynamic compromise requiring cardiopulmonary resuscitation (CPR)
  • Inability to obtain CT angiograms for follow-up
  • Previously diagnosed with Marfan syndrome, Loeys- Dietz syndrome or Ehlers- Danlos syndrome with confirmed laboratory genetic testing on a date prior to the diagnosis of the dissection

Anatomical Exclusion Criteria

  • Any pathology of mycotic origin
  • Subacute or chronic dissection of the ascending aorta and aortic arch (>14 days after the index event)
  • Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)
  • Extensive thrombus or calcifications in the aortic arch as defined by CT angiography
  • Excessive tortuosity precluding safe passage of the AMDS as defined by CT angiography
  • Descending thoracic aneurysm involving the proximal third (1/3) of the descending aorta and measuring > 45mm in diameter.

Treatment and study plan

AMDS

Device

The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.

Primary outcomes

  1. Number of participants with device-related mortality

    Time frame: Early (within 30 days)

    The number of patients with mortality related to the treatment device

  2. Number of participants with device-related mortality

    Time frame: Intermediate (3 months)

    The number of patients with mortality related to the treatment device

  3. Number of participants with device-related mortality

    Time frame: Late (6 months)

    The number of patients with mortality related to the treatment device

  4. Number of participants with neurological complications (TIA, stroke)

    Time frame: Early (within 30 days)

    The number of patients with neurological complications related to the treatment device

  5. Number of participants with neurological complications (TIA, stroke)

    Time frame: Intermediate (3 months)

    The number of patients with neurological complications related to the treatment device

  6. Number of participants with neurological complications (TIA, stroke)

    Time frame: Late (6 months)

    The number of patients with neurological complications related to the treatment device

Secondary outcomes

  1. Thrombosis of the false lumen within the confines of the device

    Time frame: Annually, through study completion, an average of 5 years

    Efficacy outcome: Number of participants with false lumen exclusion within the treatment area confined by the treatment device.

  2. Assess need for stent removal

    Time frame: Annually, through study completion, an average of 5 years

    Stent placement and retention. The number of patients requiring removal of the stent.

  3. Successful reattachment of the intimal flap within the arch

    Time frame: Annually, through study completion, an average of 5 years

    The number of patients that has successful reattachment of the intimal flap within the arch following the implantation of AMDS

  4. Successful device deployment, and radiographic evidence of false lumen exclusion within the confines of the device

    Time frame: Annually, through study completion, an average of 5 years

    The number of patients which has successful AMDS deployment and which also had radiographic evidence of false lumen exclusion within the confines of AMDS

Other outcomes

  1. Aortic injury associated with the implantation of the device

    Time frame: Annually, through study completion, an average of 5 years

    The number of patients which has any aortic injury(ies) associated with the implantation of AMDS

  2. Aortic arch branch vessel patency

    Time frame: Annually, through study completion, an average of 5 years

    An evaluation of the patency of aortic arch branch vessels for patients which have had AMDS implantation. Aortic arch branch vessel patency will be evaluated by CTA with a Core Imaging Lab.

  3. AMDS related re-interventions after the dissection repair

    Time frame: Annually, through study completion, an average of 5 years

    The number of patients which have required re-interventions related to the AMDS implantation following the index procedure for aortic dissection repair.

Sponsors and collaborators

Lead sponsor

Ascyrus Medical LLC.

Industry

Collaborators

  • Artivion Inc.

Registry information

Official study title

Dissected Aorta Repair Through Stent Implantation (DARTS): A Feasibility Study

Acronym: DARTS I

Important dates

Study start
2017
Primary completion
2019
Study completion
2024
First posted
Jan 30, 2017
Registry last updated
Aug 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.